| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Multiple targets including gut microbiota, VEGF signaling, and inflammatory pathways. 6'-Sialyllactose is a human milk oligosaccharide that modulates the gut microbiota by promoting beneficial bacteria (Bifidobacterium and Lactobacillus) and inhibiting harmful bacteria. It also exhibits anti-inflammatory activity and inhibits VEGF-mediated angiogenesis through inhibition of the Akt-ERK signaling pathway.
|
|---|---|
| ln Vitro |
In a dose-dependent manner, 6'-Sialyllactose (10 mg/mL) as supplemented with newborn formula inhibits necrotizing enterocolitis (NEC) in mice [1].
6'-Sialyllactose promotes the growth of beneficial bacteria (such as Bifidobacterium and Lactobacillus) and inhibits the proliferation of harmful bacteria. It exhibits anti-inflammatory and anti-angiogenic activities. The compound inhibits VEGF-mediated angiogenesis through inhibition of Akt-ERK signaling. These activities demonstrate its pleiotropic bioactivity as a prebiotic and immunomodulatory agent. |
| ln Vivo |
In vivo, 6'-Sialyllactose alleviates anxiety through modulation of the gut microbiota-brain axis. It alleviates benign prostatic hyperplasia by inhibiting VEGF-mediated angiogenesis (via inhibition of Akt-ERK signaling). The compound also increases muscle mass and strength to enhance exercise endurance. These effects demonstrate its potential for applications in gut health, metabolic disorders, and age-related conditions.
|
| Enzyme Assay |
In vitro binding and functional assays for 6'-Sialyllactose are used to characterize its activity. For its prebiotic activity, bacterial growth assays are performed using Bifidobacterium and Lactobacillus species cultured with increasing concentrations of 6'-SL to measure promotion of growth. For anti-angiogenic activity, endothelial cell tube formation assays are performed to assess inhibition of VEGF-induced angiogenesis.
|
| Cell Assay |
Cellular assays for 6'-Sialyllactose involve treating intestinal epithelial cells, immune cells, or endothelial cells with the compound. Readouts include measurement of inflammatory cytokine production (for anti-inflammatory activity), inhibition of VEGF-induced signaling (for anti-angiogenic activity), and assessment of gut barrier function. These assays confirm the compound's pleiotropic bioactivities in a cellular context.
|
| Animal Protocol |
In vivo efficacy of 6'-Sialyllactose has been evaluated in animal models of anxiety, benign prostatic hyperplasia, and exercise physiology. The compound is typically administered orally. Efficacy endpoints include behavioral changes (anxiety models), reduction of prostate hyperplasia, improvement in muscle mass and strength, and modulation of gut microbiota composition.
|
| ADME/Pharmacokinetics |
6'-Sialyllactose has a molecular formula of C23H39NO19. It is a sialylated human milk oligosaccharide. The compound is supplied with high purity. It is soluble in water and should be stored under recommended conditions. As a natural oligosaccharide, its pharmacokinetic properties would be characteristic of this class, with limited absorption and metabolism in the gut.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is available for 6'-Sialyllactose. As a naturally occurring human milk oligosaccharide, it is generally recognized as safe for consumption. Standard safety assessments would be required for therapeutic applications.
|
| References |
|
| Additional Infomation |
6'-Sialyllactose (6'-SL, CAS#: 35890-39-2) is a sialylated human milk oligosaccharide and one of the most abundant oligosaccharides in human milk. It has the molecular formula C23H39NO19. 6'-Sialyllactose promotes beneficial bacteria growth, exhibits anti-inflammatory and anti-angiogenic activities, alleviates anxiety, and improves muscle mass and strength. It is a research tool for studying gut health, metabolic disorders, and age-related conditions and is not approved for clinical use.
|
| Molecular Formula |
C23H39NO19
|
|---|---|
| Molecular Weight |
633.55
|
| Exact Mass |
633.212
|
| CAS # |
35890-39-2
|
| PubChem CID |
643987
|
| Appearance |
White to off-white solid powder
|
| Density |
1.72 g/cm3
|
| Boiling Point |
1134.9ºC at 760 mmHg
|
| Flash Point |
640.1ºC
|
| LogP |
-8
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
43
|
| Complexity |
927
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
CC(=O)N[C@@H]1[C@H](C[C@@](O[C@H]1[C@@H]([C@@H](CO)O)O)(C(=O)O)OC[C@@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C=O)O)O)O)O)O)O
|
| InChi Key |
VMWYCXKMRSTDSP-GIGDJUIZSA-N
|
| InChi Code |
InChI=1S/C23H39NO19/c1-7(28)24-13-8(29)2-23(22(38)39,43-20(13)15(34)10(31)4-26)40-6-12-16(35)17(36)18(37)21(41-12)42-19(11(32)5-27)14(33)9(30)3-25/h3,8-21,26-27,29-37H,2,4-6H2,1H3,(H,24,28)(H,38,39)/t8-,9-,10+,11+,12+,13+,14+,15+,16-,17-,18+,19+,20+,21-,23+/m0/s1
|
| Chemical Name |
(2R,4S,5R,6R)-5-acetamido-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-[(2R,3R,4R,5R)-1,2,4,5-tetrahydroxy-6-oxohexan-3-yl]oxyoxan-2-yl]methoxy]oxane-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5784 mL | 7.8920 mL | 15.7841 mL | |
| 5 mM | 0.3157 mL | 1.5784 mL | 3.1568 mL | |
| 10 mM | 0.1578 mL | 0.7892 mL | 1.5784 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
